| 2025-11-20 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.53美元,归母净利润-1669.6万美元,同比去年增长36.56%
|
| 2025-11-20 |
财报披露：
美东时间 2025-11-20 盘前发布财报
|
| 2025-09-30 |
详情>>
股本变动：
变动后总股本1282.14万股
变动原因 ▼▲
- 原因：
- Ordinary shares offered 1,734,105 shares by the company
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-1.3美元,归母净利润-1404.4万美元,同比去年增长12.41%
|
| 2025-05-21 |
详情>>
业绩披露：
2025年一季报每股收益-0.07美元,归母净利润-72.6万美元,同比去年增长92.54%
|
| 2025-04-07 |
股东大会：
将于2025-05-15召开股东大会
会议内容 ▼▲
- 1.Re-election of each of Messrs. Nachum (Homi) Shamir, Dr. Vickie R. Driver, David Fox, Shmuel (Milky) Rubinstein, and Stephen T. Wills to the Company’s board of directors, or Board, to serve until the next annual general meeting of shareholders of the Company and until their respective successors are duly appointed and qualified, or until their earlier resignation or removal;
2.Reappointment of Somekh Chaikin, a member firm of KPMG, as the Company’s independent registered public accounting firm for the year ending December 31, 2025 and for the additional period until the next annual general meeting of shareholders of the Company, and authorization of the Board (with power of delegation to its audit committee) to fix the independent registered public accounting firm’s remuneration in accordance with the volume and nature of its services;
3.Approval of the renewal for an additional three-year period of an updated version of the compensation policy for the executive officers and directors of the Company, or the Compensation Policy, in accordance with the requirements of the Israeli Companies Law, 5759-1999, or the Companies Law;
4.Approval of the payment of an annual cash bonus to the Company’s Chief Executive Officer, Mr. Ofer Gonen, in respect of his performance in 2024.
|
| 2025-03-19 |
详情>>
业绩披露：
2022年年报每股收益-3.93美元,归母净利润-1959.9万美元,同比去年增长-44.63%
|
| 2025-03-19 |
详情>>
业绩披露：
2024年年报每股收益-3.03美元,归母净利润-3022.4万美元,同比去年增长-350.03%
|
| 2024-11-26 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.72美元,归母净利润-2631.6万美元,同比去年增长-429.18%
|
| 2024-11-14 |
股东大会：
将于2024-12-19召开股东大会
会议内容 ▼▲
- 1.Adoption of the Company’s 2024 Share Incentive Plan, under which 280,375 ordinary shares will be rolled over from the Company’s expiring 2014 Equity Incentive Plan.
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-1.73美元,归母净利润-1603.4万美元,同比去年增长-477.39%
|
| 2024-05-29 |
股东大会：
将于2024-07-09召开股东大会
会议内容 ▼▲
- 1.Re-election of each of Messrs. Nachum (Homi) Shamir, Dr. Vickie R. Driver, David Fox, Shmuel (Milky) Rubinstein, and Stephen T. Wills to the Company’s board of directors, or Board, to serve until the next annual general meeting of shareholders of the Company and until their respective successors are duly appointed and qualified, or until their earlier resignation or removal.
2.Reappointment of Somekh Chaikin, a member firm of KPMG, as the Company’s independent registered public accounting firm for the year ending December 31, 2024 and for the additional period until the next annual general meeting of shareholders of the Company, and authorization of the Board (with power of delegation to its audit committee) to fix the independent registered public accounting firm’s remuneration in accordance with the volume and nature of its services.
3.Approval of an updated package of annual equity grants to current and future Board members, valued at $100,000 for the Chairman of the Board and $60,000 for every other Board member, comprised in each case of 80% options to purchase ordinary shares and 20% restricted share units, or RSUs.
4.Approval of updated cash fees for current and future Board members.
5.Approval of an increase to the annual base salary (cash) compensation of the Company’s Chief Executive Officer, Mr. Ofer Gonen.
6.Approval of annual equity grants valued at $750,000, comprised in each case of 80% options to purchase ordinary shares and 20% RSUs, which in respect of 2024 will consist of options to purchase 94,273 ordinary shares and 11,784 RSUs, for the Company’s Chief Executive Officer, Mr. Ofer Gonen.
7.Approval of the payment of an annual cash bonus to the Company’s Chief Executive Officer, Mr. Ofer Gonen, in respect of his performance in 2023.
|
| 2024-05-29 |
详情>>
业绩披露：
2024年一季报每股收益-1.05美元,归母净利润-972.9万美元,同比去年增长-163.44%
|
| 2024-03-21 |
详情>>
业绩披露：
2023年年报每股收益-0.75美元,归母净利润-671.6万美元,同比去年增长65.73%
|
| 2023-11-21 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.56美元,归母净利润-497.3万美元,同比去年增长59.04%
|
| 2023-04-20 |
股东大会：
将于2023-05-31召开股东大会
会议内容 ▼▲
- 1.Re-election of each of Messrs. Nachum (Homi) Shamir, Stephen T. Wills, David Fox and Assaf Segal, and Dr. Vickie R. Driver, to the Company’s board of directors, or Board, to serve until the next annual general meeting of shareholders of the Company, until each of their successors is duly appointed and qualified, or until any of their earlier resignation or removal.
2.Reappointment of Somekh Chaikin, a member firm of KPMG, as the Company’s independent registered public accounting firm for the year ending December 31, 2023 and for the additional period until the next annual general meeting of shareholders of the Company, and authorization of the Board (with power of delegation to its audit committee) to fix the independent registered public accounting firm’s remuneration in accordance with the volume and nature of its services.
3.Approval of an amendment to Article 6 of the Company’s Amended and Restated Articles of Association, as amended, that increases the Company’s authorized share capital from (i) 900,000 New Israeli Shekels, or NIS, consisting of 12,857,143 ordinary shares, par value NIS 0.07 per share, or ordinary shares, to (ii) NIS 1,400,000, consisting of 20,000,000 ordinary shares, par value NIS 0.07 per share.
4.Approval of an increase by 1,000,000 in the number of ordinary shares available for issuance under the Company’s 2014 Equity Incentive Plan.
5.Approval of grants of options to purchase 11,800 ordinary shares for the Company’s Chairman of the Board, and options to purchase 5,900 ordinary shares for each of the Company’s other directors, subject in each case to the approval of Proposals 3 and 4.
6.Approval of an extension to the exercise period of options to purchase ordinary shares that had been granted to certain directors.
7.Approval of the payment of an annual cash bonus to Mr. Ofer Gonen, the Company’s Chief Executive Officer, in respect of his performance in 2022.
8.Approval of an equity grant, comprised of options to purchase 86,000 ordinary shares, to Mr. Ofer Gonen, the Company’s Chief Executive Officer, subject to the approval of Proposals 3 and 4.
|
| 2022-12-20 |
详情>>
拆分方案：
每7.0000合并分成1.0000股
|
| 2022-10-21 |
股东大会：
将于2022-11-28召开股东大会
会议内容 ▼▲
- 1.To approve the renewal for an additional three-year period of an updated version of the compensation policy for the executive officers and directors of the Company, or the Compensation Policy, in accordance with the requirements of the Israeli Companies Law, 5759-1999, or the Companies Law.
2.To approve an amendment to Article 6 of the Company’s Amended and Restated Articles of Association, as amended, that increases the Company’s authorized share capital from (i) 500,000 New Israeli Shekels, or NIS, consisting of 50,000,000 ordinary shares, par value NIS 0.01 per share, to (ii) NIS 900,000, consisting of 90,000,000 ordinary shares, par value NIS 0.01 per share.
3.To approve a reverse share split of the Company’s ordinary shares in a range of between 5:1 and 10:1, to be effected at the discretion of, and at such ratio and on such date as shall be determined by, the Company’s board of directors, or the Board, within 12 months of the Meeting, and to amend the Company’s Amended and Restated Articles of Association accordingly.
4.To approve the compensation terms of Mr. Nachum (Homi) Shamir in his capacity as Chairman of the Board, as previously approved by the Board on August 18, 2022, effective as of the date of his appointment.
|
| 2022-06-09 |
股东大会：
将于2022-07-19召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Messrs. Stephen T. Wills, David Fox and Assaf Segal, and Dr. Vickie R. Driver (who are incumbent, non-external directors), and elect Mr. Sharon Malka (as a new non-external director), to the Company’s board of directors, or Board, to serve until the next annual general meeting of shareholders of the Company, until each of their successors is duly appointed and qualified, or until any of their earlier resignation or removal.
2.To approve the re-appointment of Somekh Chaikin, a member firm of KPMG, as the Company’s independent registered public accounting firm until the next annual general meeting of shareholders of the Company and to authorize the Board (with power of delegation to its audit committee) to fix the independent registered public accounting firm’s remuneration in accordance with the volume and nature of its services.
3.To approve an amendment to the form of indemnification letter to which the Company is party with its current and future directors and executive officers.
4.To approve and ratify the terms of the Company’s renewed Directors and Officers liability insurance policy for the period from April 1, 2022 through March 31, 2023.
5.To approve grants of options to purchase 75,000 ordinary shares for the Company’s Executive Chairman of the Board, and options to purchase 37,500 ordinary shares for each of the Company’s other directors.
6.To approve payment of an annual cash bonus to Mr. Sharon Malka, the Company’s outgoing Chief Executive Officer, in respect of his performance in 2021.
7.To approve the compensation terms of Mr. Ofer Gonen as the Company’s new Chief Executive Officer, which terms will be effective as of July 1, 2022.
8.To approve payment of a cash severance payment to Mr. Sharon Malka, the Company’s outgoing Chief Executive Officer.
9.To approve active director service terms for Mr. Sharon Malka, the Company’s outgoing Chief Executive Officer.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-07-20 |
复牌提示：
2021-07-20 06:56:33 停牌，复牌日期 2021-07-20 07:30:00
|
| 2021-05-05 |
股东大会：
将于2021-06-15召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Messrs. Stephen T. Wills, Ofer Gonen, Assaf Segal, David Fox, and Samuel Moed, and Dr. Vickie R. Driver (who are incumbent, non-external directors), to the Board, to serve until the next annual general meeting of shareholders of the Company, until each of their successors is duly appointed and qualified, or until any of their earlier resignation or removal.
2.To approve the appointment of Somekh Chaikin, a member firm of KPMG, as the Company’s independent registered public accounting firm until the next annual general meeting of shareholders of the Company and to authorize the Board (with power of delegation to its audit committee) to fix the independent registered public accounting firm’s remuneration in accordance with the volume and nature of its services.
3.To approve an amendment to the form of indemnification letter to which we are party with our current and future directors and executive officers.
4.To approve and ratify the terms of the Company’s renewed Directors and Officers liability insurance policy for the period from April 1, 2021 through March 31, 2022.
5.To approve an amendment to the Company's Articles of Association (the “Articles”) that sets the forum for adjudication of disputes under the Articles.
6.To approve grants of options to purchase 22,500 ordinary shares and 3,750 RSU's for our Executive Chairman of the Board, and options to purchase 11,250 ordinary shares and 1,875 RSUs for each of our other directors.
7.To approve the renewal of the Registration Rights Agreement to which the Company is party with Clal Life Sciences LP, Clal Biotechnology Industries Ltd., Professor Lior Rosenberg and L.R. Research & Development Ltd. (as trustee for the benefit of Professor Lior Rosenberg).
8.To approve payment of an annual cash bonus to Mr. Sharon Malka, our Chief Executive Officer, in respect of his performance in 2020.
9.To approve an equity grant, comprised of options to purchase 45,692 ordinary shares, and 7,615 RSUs, to Mr. Sharon Malka, our Chief Executive Officer.
|
| 2020-05-20 |
股东大会：
将于2020-06-29召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Messrs. Stephen T. Wills, David Fox, Ofer Gonen, Sam Moed and Assaf Segal, and Dr. Vickie R. Driver (who are incumbent directors), to the Company’s Board of Directors, or the Board, to serve until the next annual general meeting of shareholders of the Company, until each of their successors is duly appointed and qualified, or until any of their earlier resignation or removal.
2.To re-elect each of Messrs. Sharon Kochan and Nissim Mashiach to serve as an external director under the Israeli Companies Law, 5759-1999, or the Companies Law, for a period of three years.
3.To approve the re-appointment of Kost Forer Gabbay and Kasierer, a member firm of Ernst & Young Global, as the Company’s independent registered public accounting firm until the next annual general meeting of shareholders of the Company and to authorize the Board (with power of delegation to its audit committee) to fix the independent registered public accounting firm’s remuneration in accordance with the volume and nature of its services.
4.To approve and ratify the terms of the Company’s renewed Directors and Officers liability insurance policy for the period from April 1, 2020 through March 31, 2021.
5.To approve updated director fee package (covering fees for Board and Board committee service) for all directors, excluding the Chairman of the Board.
6.To approve grants of options to purchase 100,000 of the Company’s ordinary shares, par value 0.01 New Israeli Shekels per share, or ordinary shares, for each of the Company’s directors, and additional grants of options to purchase ordinary shares and/or restricted share units, or RSUs, of $35,000 value each, to the external directors as of the dates of the Company’s next two annual shareholder meetings.
7.To approve a cash bonus for the Executive Chairman of the Board, Stephen T. Wills, in respect of his role in the Company’s transaction with Vericel Corporation for the commercialization of the Company’s product, NexoBrid, in North America.
8.To approve payment of an annual cash bonus to Mr. Sharon Malka, the Company’s Chief Executive Officer, in respect of his performance in 2019.
9.To approve a grant of options to purchase 81,170 ordinary shares to Mr. Sharon Malka, the Company’s Chief Executive Officer.
10.To approve a cash bonus for Mr. Gal Cohen, the Company’s previous President and Chief Executive Officer, in respect of his role in the Company’s transaction with Vericel Corporation for the commercialization of NexoBrid in North America.
|
| 2019-08-14 |
股东大会：
将于2019-09-26召开股东大会
会议内容 ▼▲
- 1.To approve an updated compensation policy for the executive officers and directors of our Company, or the Compensation Policy, in accordance with the requirements of the Israeli Companies Law, 5759-1999, or the Companies Law;
2.To approve an amendment to Article 6 of our Company’s Articles of Association, as amended, that increases our authorized share capital from 372,445.08 New Israeli Shekels, or NIS, divided into 37,244,508 ordinary shares, par value NIS 0.01 each, to NIS 500,000 divided into fifty million (50,000,000) ordinary shares, par value NIS 0.01 each.
|
| 2019-03-25 |
股东大会：
将于2019-05-02召开股东大会
会议内容 ▼▲
- (1)To approve the re-election of each of Messrs. Stephen T. Wills, Ofer Gonen and Assaf Segal, and Dr. Vickie R. Driver (who are incumbent directors), to the Company’s Board of Directors, or the Board, to serve until the next annual general meeting of shareholders of the Company, until each of their successors is duly appointed and qualified, or until any of their earlier resignation or removal;
(2)To approve the re-appointment of Kost Forer Gabbay and Kasierer, a member firm of Ernst & Young Global, as the Company’s independent registered public accounting firm until the next annual general meeting of shareholders of the Company and authorize the Board (with power of delegation to its audit committee) to fix the independent registered public accounting firm’s remuneration in accordance with the volume and nature of its services;
(3)To approve the compensation terms of Mr. Sharon Malka as the Company’s new Chief Executive Officer, which terms will be effective as of January 1, 2019;
(4)To approve increased annual director fees, effective as of January 1, 2019, and a grant of options to purchase the Company’s ordinary shares, par value 0.01 New Israeli Shekels per share, or ordinary shares, and restricted share units, or RSUs, to Mr. Stephen T. Wills, our Chairman of the Board, in respect of his new enhanced role as active Chairman of the Board;
(5)To approve payment of a cash severance fee to Mr. Gal Cohen, our outgoing President and Chief Executive Officer;
(6)To approve the 2018 annual cash bonus for Mr. Gal Cohen, our outgoing President and Chief Executive Officer, in respect of his performance in 2018;
(7)To approve and ratify the Company’s renewed director and officer liability insurance policy for the period from April 1, 2019 through March 31, 2020.
|
| 2018-05-10 |
股东大会：
将于2018-06-18召开股东大会
会议内容 ▼▲
- 1.To approve the re-election of each of Messrs. Stefan T. Wills, Ofer Gonen and Assaf Segal, and Dr. Vickie R. Driver (who are incumbent directors), to the Company’s Board of Directors, or the Board, to serve until the next annual general meeting of shareholders of the Company, until each of their successors is duly appointed and qualified, or until any of their earlier resignation or removal;
2.To approve the re-appointment of Kost Forer Gabbay and Kasierer, a member firm of Ernst & Young Global, as the Company’s independent registered public accounting firm until the next annual general meeting of shareholders of the Company and authorize the Board (with power of delegation to its audit committee) to fix the independent registered public accounting firm’s remuneration in accordance with the volume and nature of its services;
3.To approve an amendment to our Articles of Association to increase the number of ordinary shares we are authorized to issue from 32,244,508 ordinary shares to 37,244,508 ordinary shares and correspondingly increase the authorized share capital of our Company from NIS 322,445.08 to NIS 372,445.08;
4.To approve the 2017 annual bonus for, and amendment to the terms of engagement of, Gal Cohen, our President and Chief Executive Officer.
|
| 2018-01-16 |
股东大会：
将于2018-02-22召开股东大会
会议内容 ▼▲
- 1.To approve the terms of office and engagement of Mr. Stephen T. Wills, the Chairman of our Board of Directors;
2.To approve amendments to the terms of engagement of Gal Cohen, our President and Chief Executive Officer;
3.To approve an amendment to the terms of options to purchase ordinary shares that had been granted to Gal Cohen, our President and Chief Executive Officer
|
| 2016-05-04 |
股东大会：
将于2016-06-09召开股东大会
会议内容 ▼▲
- 1. To approve the re-election each of Messrs. Aharon Yaari, Ofer Gonen, Meron Mann and Dr. Marian Gorecki (the Company’s incumbent directors who are not external directors) to the Company’s Board of Directors, or the Board, to serve until the next annual general meeting of shareholders of the Company, until each of their successors is duly appointed and qualified, or until any of their earlier resignation or removal;
2. To approve the re-appointment of Kost Forer Gabbay and Kasierer, a member firm of Ernst & Young Global, as the Company’s independent registered public accounting firm until the next annual general meeting of shareholders of the Company and authorize the Board (with power of delegation to its audit committee) to fix the said independent registered public accounting firm’s remuneration in accordance with the volume and nature of its services.
3. To approve the 2015 annual bonus of Gal Cohen, our President and Chief Executive Officer;
4. To approve an extension of the exercise period of certain options to purchase the Company’s ordinary shares granted to Gal Cohen, our President and Chief Executive Officer.
|
| 2015-12-23 |
股东大会：
将于2016-01-28召开股东大会
会议内容 ▼▲
- 1.To approve the terms of office and engagement of Mr. Aharon Yaari, who will serve as Chairman of our Board of Directors beginning on January 1, 2016;
2.To approve the grants to our President and Chief Executive Officer of options to purchase ordinary shares of the Company under the Company’s 2014 Share Incentive Plan;
3.To approve and ratify in all respects a one-time bonus to the Company’s President and Chief Executive Officer.
|
| 2015-08-05 |
股东大会：
将于2015-09-10召开股东大会
会议内容 ▼▲
- 1. To approve each of Messrs. Ruben Krupik, Ofer Gonen, Meron Mann and Dr. Marian Gorecki (the Company’s incumbent directors who are not external directors) to the Board, to serve until the next annual general meeting of shareholders of the Company, until each of their successors is duly appointed and qualified, or until any of their earlier resignation or removal;
2. To approve the re-appointment of Kost Forer Gabbay and Kasierer, a member firm of Ernst & Young Global, as the Company’s independent registered public accounting firm until the next annual general meeting of shareholders of the Company and authorize the Board (with power of delegation to its audit committee) to fix the said independent registered public accounting firm’s remuneration in accordance with the volume and nature of its services;
3. To approve an amendment to the terms of employment of Prof. Lior Rosenberg, our Chief Medical Technology Officer.
|